Karyopharm Therapeutics

Health biotech drug development oncology pharma

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1. Karyopharm is seeking the regulatory approval and commercialization of its lead drug candidate, selinexor (KPT-330), as a single orally administered agent in cancer indications with unmet clinical need, initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.

Type

Subsidiary

Parent Company

Biogen

Newton, US

Founded

2008

Website

karyopharm.com

Karyopharm Therapeutics was founded in 2008 and is headquartered in Newton, US

Report incorrect company information

Key People/Management at Karyopharm Therapeutics

Michael Kauffman

Chief Executive Officer &Board of Directors

John McCartney

Senior Director, Product Leadership

Brian Austad

Vice President, Head of Pharmaceutical Sciences

Dilara McCauley

Vice President, Product Leadership

Report incorrect company information

Karyopharm Therapeutics Office Locations

Karyopharm Therapeutics has offices in Newton and München

Newton, US (HQ)

85 Wells Ave

München, DE

9 Franziska-Bilek-Weg

Show all (2)

Report incorrect company information

Karyopharm Therapeutics Financials and Metrics

Summary Metrics

Founding Date	2008
Total Funding	$248.7 m
Investors	Delphi Ventures, New Leaf Venture Partners, Foresite Capital

Karyopharm Therapeutics is a subsidiary of Biogen

Karyopharm Therapeutics Financials

Karyopharm Therapeutics's revenue was reported to be $250 k in FY, 2015 which is a 9.2% increase from the previous period.

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Revenue	387 k	229 k	250 k
Revenue growth, %		(41%)	9%
General and administrative expense	5.9 m	15.9 m	21.6 m	23.9 m
R&D expense	28.5 m	60.1 m	97.7 m	86.9 m

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
General and administrative expense	2.9 m	3.3 m	3.8 m	5.4 m	6.2 m	4.8 m	5.6 m	6 m	5.9 m	6.3 m	6.6 m	5.8 m
R&D expense	11 m	13.2 m	16 m	20.8 m	27 m	25.9 m	21.8 m	24.6 m	19.9 m	24.1 m	23.1 m	25.2 m
Operating expense total	13.9 m	16.5 m	19.8 m	26.2 m	33.2 m	30.7 m	27.3 m	30.5 m	25.8 m	30.3 m	29.8 m	31.1 m
EBIT	(13.7 m)	(16.4 m)	(19.7 m)	(26.2 m)	(33 m)	(30.6 m)	(27.3 m)	(30.5 m)	(25.7 m)	(30.3 m)	(29.8 m)	(31.1 m)

show all

Source: SEC Filings

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Cash	156 m	150.6 m	58.4 m	49.7 m
Inventories	2 m	2 m	2 m	2.1 m
Current Assets	158 m	207.8 m	177.6 m	131.6 m

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Cash	144.9 m	132.3 m	227.1 m	51.5 m	24.2 m	43.5 m	42.2 m	37.7 m	43.9 m	25.6 m	55.4 m	54.5 m
Current Assets	147.6 m	135.3 m	231.3 m	249.3 m	225.3 m	198.3 m	138.1 m	124.2 m	130.3 m	112.2 m	145.7 m	121.7 m
PP&E	322 k	604 k	2.7 m	3.3 m	3.2 m	3.7 m	3.3 m	3.2 m	3 m	2.7 m	2.5 m	2.3 m
Total Assets	149.3 m	137.7 m	235.2 m	292 m	263.3 m	237 m	192.1 m	170.9 m	183.6 m	155.4 m	185.8 m	163.8 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Net Income	(33.9 m)	(75.8 m)	(118.2 m)	(109.6 m)
Depreciation and Amortization	144 k	323 k	634 k	717 k
Inventories	(1.4 m)	(45 k)	(55 k)	(120 k)
Accounts Payable	664 k	4.5 m	(2.4 m)	945 k